Loop-Mediated Isothermal Amplification Assay for Detecting Tumor Markers and Human Papillomavirus: Accuracy and Supplemental Diagnostic Value to Endovaginal MRI in Cervical Cancer

Isothermal Technologies for HPV Detection: Current Trends and Future Perspectives

The human papillomavirus (HPV) is a non-enveloped DNA virus transmitted through skin-to-skin contact that infects epithelial and mucosal tissue. It has over 200 known genotypes, classified by their pathogenicity as high-risk and low-risk categories. High-risk HPV genotypes are associated with the development of different types of cancers, including cervical cancer, which is a leading cause of mortality in women. In clinical practice and the market, the principal tests used to detect HPV are based on cytology, hybrid detection, and qPCR. However, these methodologies may not be ideal for the required timely diagnosis. Tests have been developed based on isothermal nucleic acid amplification tests (INAATs) as alternatives. These tests offer multiple advantages over the qPCR, such as not requiring specialized laboratories, highly trained personnel, or expensive equipment like thermocyclers. This review analyzes the different INAATs applied for the detection of HPV, considering the specific characteristics of each test, including the HPV genotypes, gene target, the limit of detection (LOD), detection methods, and detection time. Additionally, we discuss the tests available on the market that are approved by the Food and Drug Administration (FDA). Finally, we address the challenges and potential solutions for the large-scale implementation of INAATs, particularly in rural or underserved areas.

Endovaginal coil for pelvic high-resolution magnetic resonance imaging of cervical cancer: a preliminary parameter optimization study

Background

The diagnosis of early-stage cervical cancer through conventional magnetic resonance imaging (MRI) remains challenging, highlighting a greater need for pelvic high-resolution MRI (HR MRI). This study used our research team's endovaginal coil imaging to optimize scanning parameters and aimed to achieve HR MRI of the pelvis and determine its clinical value.

Methods

Fifty participants were recruited prospectively for this cross-sectional study conducted at the First Affiliated Hospital of Chongqing Medical University from January 2023 to November 2023. Initially, 10 volunteers requiring pelvic imaging diagnosis underwent pelvic MRI with the endovaginal coil combined with a conventional external array coil to test and optimize the scanning parameters. Subsequently, 40 patients who were highly suspected or diagnosed with cervical cancer were randomly assigned to undergo an initial pelvic scan with an external array coil with subsequent examinations of both the conventional coil and the endovaginal coil. Two experienced radiologists performed quantitative analyses, measuring signals and calculating the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and contrast (C). They also conducted qualitative analyses, evaluating imaging artifacts, anatomical structures, and overall image quality. The paired sample t-test and Wilcoxon rank-sum test were conducted to compare the statistical differences between the two sets of images, while the intraclass correlation coefficient (ICC) and Kappa consistency tests were used to assess the measurement and scoring consistency between the two radiologists.

Results

The optimized endovaginal images had higher mean SNR, CNR, and C values (18.62±7.85, 16.04±7.72, and 0.73±0.11, respectively) compared to the conventional images (6.77±2.36, 4.47±2.05, and 0.47±0.12, respectively). Additionally, the ratings for imaging artifacts, anatomical structures, and overall quality of the endovaginal images were all 4 [interquartile range (IQR) 4, 4]; meanwhile, the conventional images scored lower with ratings of 4 (IQR 3, 4), 3 (IQR 3, 3), and 3 (IQR 3, 3) for SNR, CNR, and C, respectively. All analysis results underwent paired-sample t-tests or Wilcoxon rank-sum tests between the two groups, yielding a P value <0.001. The optimized endovaginal images also showed improved resolution with a reconstructed voxel size of 0.11 mm3, and HR MRI was successfully achieved. The ICC values for the measurements were 0.914, 0.947, and 0.912, respectively, and for the ratings, the measurement was 0.923, indicating excellent consistency between the two physicians (ICC/Kappa value between 0.85 and 1.00).

Conclusions

Endovaginal technology, which provides precise clinical information for the diagnosis of cervical cancer, provides straightforward operation and exceptional imaging quality, making it highly suitable for expanded clinical use.

Advanced technologies towards improved HPV diagnostics

Persistent infection with high-risk types of human papillomaviruses (HPV) is a major cause of cervical cancer, and an important factor in other malignancies, for example, head and neck cancer. Despite recent progress in screening and vaccination, the incidence and mortality are still relatively high, especially in low-income countries. The mortality and financial burden associated with the treatment could be decreased if a simple, rapid, and inexpensive technology for HPV testing becomes available, targeting individuals for further monitoring with increased risk of developing cancer. Commercial HPV tests available in the market are often relatively expensive, time-consuming, and require sophisticated instrumentation, which limits their more widespread utilization. To address these challenges, novel technologies are being implemented also for HPV diagnostics that include for example, isothermal amplification techniques, lateral flow assays, CRISPR-Cas-based systems, as well as microfluidics, paperfluidics and lab-on-a-chip devices, ideal for point-of-care testing in decentralized settings. In this review, we first evaluate current commercial HPV tests, followed by a description of advanced technologies, explanation of their principles, critical evaluation of their strengths and weaknesses, and suggestions for their possible implementation into medical diagnostics.

VIDIIA Hunter diagnostic platform: a low-cost, smartphone connected, artificial intelligence-assisted COVID-19 rapid diagnostics approved for medical use in the UK

Introduction: Accurate and rapid diagnostics paired with effective tracking and tracing systems are key to halting the spread of infectious diseases, limiting the emergence of new variants and to monitor vaccine efficacy. The current gold standard test (RT-qPCR) for COVID-19 is highly accurate and sensitive, but is time-consuming, and requires expensive specialised, lab-based equipment. Methods: Herein, we report on the development of a SARS-CoV-2 (COVID-19) rapid and inexpensive diagnostic platform that relies on a reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay and a portable smart diagnostic device. Automated image acquisition and an Artificial Intelligence (AI) deep learning model embedded in the Virus Hunter 6 (VH6) device allow to remove any subjectivity in the interpretation of results. The VH6 device is also linked to a smartphone companion application that registers patients for swab collection and manages the entire process, thus ensuring tests are traced and data securely stored. Results: Our designed AI-implemented diagnostic platform recognises the nucleocapsid protein gene of SARS-CoV-2 with high analytical sensitivity and specificity. A total of 752 NHS patient samples, 367 confirmed positives for coronavirus disease (COVID-19) and 385 negatives, were used for the development and validation of the test and the AI-assisted platform. The smart diagnostic platform was then used to test 150 positive clinical samples covering a dynamic range of clinically meaningful viral loads and 250 negative samples. When compared to RT-qPCR, our AI-assisted diagnostics platform was shown to be reliable, highly specific (100%) and sensitive (98-100% depending on viral load) with a limit of detection of 1.4 copies of RNA per µL in 30 min. Using this data, our CE-IVD and MHRA approved test and associated diagnostic platform has been approved for medical use in the United Kingdom under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals, CTDA) Regulations 2022. Laboratory and in-silico data presented here also indicates that the VIDIIA diagnostic platform is able to detect the main variants of concern in the United Kingdom (September 2023). Discussion: This system could provide an efficient, time and cost-effective platform to diagnose SARS-CoV-2 and other infectious diseases in resource-limited settings.